Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

Technology Scientific & Technical Instruments
RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair... see more

Recent & Breaking News (TSXV:RP)

RepliCel Retains O&M Partners to Coordinate North American Focused Investor Marketing Campaign

Marketwired June 20, 2014

RepliCel Life Sciences Announces Closing of Third and Final Tranche of Private Placement

Marketwired June 17, 2014

RepliCel Retains Christina Cameron as Canadian Investor Relations Consultant

Marketwired June 5, 2014

RepliCel Life Sciences Inc. Announces Closing of Second Tranche of Private Placement

Marketwired May 21, 2014

RepliCel Life Sciences' Licensing Partner, Shiseido, Opens Cell Processing and Expansion Facility in Japan to Advance RCH-01, a Treatment for Pattern Baldness

Marketwired May 20, 2014

RepliCel Life Sciences Inc. Announces Closing of Brokered and Non-Brokered Private Placement

Marketwired May 9, 2014

RepliCel Life Sciences Announces Brokered Private Placement

Marketwired March 28, 2014

RepliCel Life Sciences Announces Brokered Private Placement

Marketwired March 28, 2014

RepliCel Reports 2013 Annual Financial Results

Marketwired March 18, 2014

RepliCel to Present RCH-01 Phase 1 Clinical Data at the 13th Congress of the Japanese Society for Regenerative Medicine

Marketwired February 27, 2014

RepliCel Receives Japanese Patent Covering its Hair Regeneration Technology

Marketwired January 13, 2014

RepliCel to Commence Trading on the TSX Venture Exchange

Marketwired January 9, 2014

RepliCel Life Sciences to Present at Biotech Showcase(TM) 2014

Marketwired January 9, 2014

Replicel Announces Conditional Approval from TSX Venture Exchange

Marketwired January 2, 2014

RepliCel Reports Progress on Shiseido Technology Transfer for RCH-01 Treatment for Pattern Baldness

Marketwired December 19, 2013

Small cap results digest: RepliCel Life Sciences (C.RP) rockets, Photon Control (V.PHO) performs and Sterling Resources (V.SLG) slips

Gaalen Engen November 20, 2013

RepliCel Reports Third Quarter 2013 Financial Results and Provides Corporate Update

Marketwired November 20, 2013

RepliCel Forms Clinical Advisory Board to Support the Development of RCT-01 for the Treatment of Chronic Tendinosis

Marketwired October 30, 2013

RepliCel Announces Stock Option Grant

Marketwired September 6, 2013

RepliCel Retains Westwicke Partners as Investor Relations Counsel

Marketwired September 4, 2013